Thymmune is a biotechnology company developing a machine learning-enabled thymic cell engineering platform to restore normal immune function in aging and disease. The company's cutting-edge approach in iPSC-thymic cell manufacturing can generate off-the-shelf cells at scale. The company is developing a pipeline of therapies to treat immunodeficiencies, transplant related, and autoimmune diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/01/23 | $7,000,000 | Seed |
NYBC Ventures Pillar VC | undisclosed |
